The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.
M. S. Roh
No relevant relationships to disclose
G. A. Yothers
No relevant relationships to disclose
M. J. O'Connell
Consultant or Advisory Role - Roche; Sanofi
R. W. Beart
No relevant relationships to disclose
H. C. Pitot
No relevant relationships to disclose
A. F. Shields
No relevant relationships to disclose
D. S. Parda
No relevant relationships to disclose
S. Sharif
No relevant relationships to disclose
C. J. Allegra
Consultant or Advisory Role - Genentech
N. J. Petrelli
Consultant or Advisory Role - Genentech (U)
J. C. Landry
No relevant relationships to disclose
D. P. Ryan
Consultant or Advisory Role - Genomic Health
A. Arora
No relevant relationships to disclose
T. L. Evans
No relevant relationships to disclose
G. S. Soori
Stock Ownership - Sanofi
L. Chu
Stock Ownership - Sanofi
Research Funding - Sanofi
R. V. Landes
No relevant relationships to disclose
M. Mohiuddin
No relevant relationships to disclose
S. Lopa
No relevant relationships to disclose
N. Wolmark
No relevant relationships to disclose